Your browser doesn't support javascript.
loading
Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).
Fokkert, Marion; van Dijk, Peter; Edens, Mireille; Barents, Eglantine; Mollema, Jeanine; Slingerland, Robbert; Gans, Reinold; Bilo, Henk.
Afiliación
  • Fokkert M; Clinical Chemistry, Isala, Zwolle, Overijssel, The Netherlands.
  • van Dijk P; Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Edens M; Department of Innovation and Science, Isala, Zwolle, Overijssel, The Netherlands.
  • Barents E; Dutch Diabetes Association, Leusden, The Netherlands.
  • Mollema J; General Practice, University of Groningen, Groningen, The Netherlands.
  • Slingerland R; Clinical Chemistry, Isala, Zwolle, Overijssel, The Netherlands.
  • Gans R; Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Bilo H; Diabetes Centre, Isala Clinics, Zwolle, The Netherlands.
BMJ Open Diabetes Res Care ; 7(1): e000809, 2019.
Article en En | MEDLINE | ID: mdl-31875133
Introduction: The FreeStyle Libre is a flash glucose monitoring (FSL-FGM) system. Compared with finger-prick based self-monitoring of blood glucose, FSL-FGM may provide benefits in terms of improved glycemic control and decreased disease burden. Methods: Prospective nationwide registry. Participants with diabetes mellitus (DM) used the FSL-FGM system for a period of 12 months. End points included changes in HbA1c, hypoglycemia, health-related quality of life (12-Item Short Form Health Surveyv2 (SF-12v2) and 3-level version of EuroQol 5D (EQ-5D-3L)), a specifically developed patient-reported outcome measures (PROMs) questionnaire, diabetes-related hospital admission rate and work absenteeism. Measurements were performed at baseline, and after 6 months and 12 months. Results: 1365 persons (55% male) were included. Mean age was 46 (16) years, 77% of participants had type 1 DM, 16% type 2 DM and 7% other forms. HbA1c decreased from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 to 61) mmol/mol with a difference of -4 (95% CI -6 to 3) mmol/mol. Persons with a baseline HbA1c >70 mmol/mol had the most profound HbA1c decrease: -9 (95% CI -12 to to 5) mmol/mol. EQ-5D tariff (0.03 (95%CI 0.01 to 0.05)), EQ-VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12v2 mental component score (3.3 (95%CI 2.1 to 4.4)) improved. For most, PROMs improved. Work absenteeism rate (/6 months) and diabetes-related hospital admission rate (/year) decreased significantly, from 18.5% to 7.7% and 13.7% to 2.3%, respectively. Conclusions: Real world data demonstrate that use of FSL-FGM results in improved well-being and decreased disease burden, as well as improvement of glycemic control.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Biomarcadores / Automonitorización de la Glucosa Sanguínea / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Hipoglucemiantes Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Diabetes Res Care Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Biomarcadores / Automonitorización de la Glucosa Sanguínea / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 / Hipoglucemiantes Tipo de estudio: Observational_studies / Prognostic_studies Aspecto: Patient_preference Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMJ Open Diabetes Res Care Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido